Shijiazhuang Pengnuo Technology Co., Ltd. www.pengnuochemical.com
Hepatitis B remains a significant global public health challenge, impacting the health and lives of hundreds of millions of patients worldwide. While current treatments can manage the condition to a certain extent, achieving a “functional cure” has always been the unwavering goal of the medical community.
Recently, there has been a major breakthrough: Yuekang Pharma’s independently developed YKYY017 injection has officially received U.S. FDA approval for clinical trials. This milestone marks another crucial step forward for China in the field of innovative hepatitis B drug R&D, demonstrating the innovative capabilities of domestic pharmaceutical companies in global new drug development.
YKYY017 injection is a small interfering RNA (siRNA) drug based on RNA interference (RNAi) technology. It not only boasts broad-spectrum antiviral potential but has also demonstrated an outstanding ability to reduce viral antigen levels in preclinical studies. It is expected to offer a breakthrough treatment option for hepatitis B patients, ultimately contributing to the goal of a functional cure.
Shijiazhuang Pengnuo Technology Co., Ltd. hereby extends its warmest congratulations to Yuekang Pharma!
Shijiazhuang Pengnuo Technology Co., Ltd. was established in 2020. We specializing in the research and development, production and sales of pharmaceutical intermediates and fine chemical products. We have one production plant and one R&D center.
2,4-Diamino-6-hydroxypyrimidine CAS： 56-06-4
2-(chloromethyl)-4-methylquinazoline CAS： 109113-72-6
1-Bromo-2-butyne CAS： 3355-28-0
1,7-Dihydroxynaphthalene CAS： 575-38-2
1,6-Naphthalenedisulfonic acid CAS： 525-37-1
1,6-Naphthalenedisulfonic acid disodium salt CAS： 1655-43-2
Post time: Sep-25-2025